Blood Sugar Control and Monitoring Over 12 Months of Tirzepatide Treatment in Overweight or Obese People with Type 1 Diabetes
Updated
Abstract
Tirzepatide treatment was associated with a 50.8% achievement rate of composite continuous glucose monitoring targets in overweight or obese adults with type 1 diabetes after 12 months.
- Tirzepatide-treated participants showed improved time in range (TIR) at multiple time points: +4.6% at 3 months, +9.0% at 6 months, +6.9% at 9 months, and +7.4% at 12 months compared to controls.
- Time in tight range (TITR) was significantly higher in the tirzepatide group at 6, 9, and 12 months.
- Mean glucose levels, time above range (TAR), and time >250 mg/dL were lower in the tirzepatide group compared to controls.
- Time below range <70 mg/dL and <54 mg/dL remained similar between tirzepatide and control groups throughout the study.
- No severe hypoglycemia or diabetic ketoacidosis occurred in either treatment group.
Simplified
Funding
Competing interests
Author Disclosure StatementH.K.A. received research support and consultation fees through University of Colorado from Roche. S.K.G. reports no personal financial disclosures relevant to this article. However, he reports the following: Advisory boards, consulting fees: Medtronic, Vertex, Abbott Diabetes Care, Novo Nordisk, and Roche Diagnostics. His institute has received research grants from: Eli Lilly, Novo Nordisk, Medtronic, and Dexcom and Diasome. He has no stocks in any device or pharmaceutical company. All research grants and honoraria go through the University of Colorado Denver.
PubMed